Versartis Raises $21M in Second Round
February 16, 2011
Versartis Inc. has completed a $21 million second round of funding. The round was led by New Leaf Venture Partners, which has an office in Menlo Park.
London-based Advent Venture Partners, Geneva-based Index Ventures and Mountain View-based Amunix Inc. also joined in the round.
Mountain View-based Versartis is biotechnology startup developing therapeutics for patients with endocrine disorders.
The company plans to use the proceeds to conduct clinical trials of its lead product, VRS-317, for growth hormone deficiency in adult and pediatric patients.
Versartis also has expanded its board of directors to five members: Dr. Srini Akkaraju, managing director of New Leaf Venture Partners; Kevin Johnson, partner at Index Ventures; Shahzad Malik, general partner at Advent Venture Partners; Willem Stemmer, CEO of Amunix; and Jeffrey L. Cleland, CEO of Versartis.
About
The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas.
Contact Us
Alliance of Chief Executives, LLC
2185 N. California Blvd.,
Suite 590
Walnut Creek, CA 94596
- 925-942-2400 Office
- 925-956-4424 Fax
- Email: info@allianceofCEOs.com
Newsletter
Subscribe to our newsletter and stay up to date with the latest Alliance news!
About
The Alliance of Chief Executives is an active community of business leaders that focuses on deep strategic exchanges, challenging existing assumptions and generating fresh ideas.
Newsletter
Subscribe to our newsletter and stay up to date with the latest Alliance news!
Member Resources
Contact Us
2185 N. California Blvd., Suite 590
Walnut Creek, CA 94596
925-942-2400 Office
925-956-4424 Fax
Email: info@allianceofCEOs.com
2022 © Alliance of Chief Executives, LLC
